Archive | Innovator’s Pitch Challenge RSS feed for this section

RESI San Diego 2017 Innovation Challenge – Winners Announced

22 Jun

By Nono Hu, Director of Marketing, LSN

On June 19, more than 600 healthcare entrepreneurs and investors entered the exhibition hall at the Westin San Diego Gaslamp Quarter. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Taithera

Taithera is redefining orthopaedics. Taithera is developing a first-in-class bone targeted drug delivery platform for the treatment of musculoskeletal disorders. The core of Taithera’s revolutionary platform is a nanoparticle that is programmed to deliver therapeutics directly to the site of a bone lesion. This hyper-targeted delivery platform can be used to treat primary and metastatic bone cancers, fractures, osteoporosis, and other bone conditions. Taithera is based in New York City, and was founded by Mo Chen, PhD and Seth Harlem.

Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera

Second Place: Tasso

Tasso is a medical device company that is developing the HemoLink, a user-friendly way to self-collect blood for clinical testing that has the potential to fundamentally change how people interface with healthcare. The HemoLink is a device that enables high-quality blood sample collection with one press of a button. After the blood draw is complete, the tube appended to the device simply twists off and can be used directly within standard lab processes. The HemoLink is enabled by novel microfluidic technologies that enable connectivity (e.g. tube types), simple low-cost manufacturing, and plasma separation onsite. The HemoLink can replace phlebotomy in small clinics and bring blood collection to the home.

Michael Quigley, VP of Market Research, Life Science Nation | Ben Casaavant, VP, Engineering, Tasso

Third Place: ViewsIQ

ViewsIQ is a medical technology company, digitizing patient samples microscopically to disrupt the pathology practice – the last remaining medical imaging field to go digital. ViewsIQ’s Panoptiq system is the first software-based approach to digital imaging that allows seamless integration into a Pathologist’s clinical workflow. With Panoptiq, the cost barrier to digital imaging has been removed, permitting clinicians to offer expert diagnostic care to patients virtually anywhere in the world.

Michael Quigley, VP of Market Research, Life Science Nation | Herman Lo, CEO, ViewsIQ

Thank you to all who competed in the RESI San Diego Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

RESI Innovation Challenge: LSN’s Scientific Review Team Selects 30 Top Life Science Startups

1 Jun

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

We are pleased to announce our thirty finalists to compete in the Innovation Challenge at Life Science Nation’s (LSN) first-ever RESI in San Diego. From a pool of approximately 100 applicants, the LSN Scientific Review Team has selected a diverse group of life science startups: three healthcare IT, three diagnostic, thirteen therapeutic, and eleven medical device companies.  These startups will showcase themselves in the exhibit hall display spaces at RESI on June 19th. The quality of these companies should not go unnoticed, as we have seen nearly 50% of Innovation Challenge finalists from previous RESI’s receive funding within one year of their debut.

From personalized cancer immunotherapies to digital pathology imaging, these companies cover a diverse range of life science technologies. Coming from all over the world, the companies will be competing based on scientific merit and investment potential, pitching to RESI attendees and showcasing their innovations. Be sure to catch them and make your “investments” at the RESI Exhibition Hall in just a couple weeks!

Therapeutic
 
Diagnostic
Medical Device
 
Healthcare IT
 

Get Your Startup in the Spotlight at the RESI Innovation Challenge in San Diego

20 Apr

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

RESI is going to BIO. As we join 2017’s largest life science innovation carnival, we aim to showcase the most promising, innovative new health technologies in the RESI Innovation Challenge. If you’re headed to San Diego with the aim of raising money or making deals for your startup, we’d like to see your application.

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On June 19th, RESI’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder, Steadiwear | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

RESI on MaRS 2017 Innovation Challenge 1st Place Winner – Steadiwear inc.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.

APPLICATION DEADLINE: May 5, 2017

Here is what our previous winners are saying about the RESI Innovation Challenge:

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
 

– Raymond Shih, President, Co-Founder, QoC Health

3rd Place, RESI on MaRS, June 23, 2016

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

30 Leading Life Science Startups Compete in Innovation Challenge at The Redefining Early Stage Investments (RESI) Conference at MaRS

9 Mar

By Michael Quigley, VP of Market Research, LSN

mike-2

As RESI gears up for its second landing on MaRs in Toronto this April 4th we are proud to announce our latest batch of life science/health tech companies that will be participating in the RESI Innovation Challenge.

30 companies from across North America, hand selected by LSN’s scientific and commercial review team, will compete directly on merits of innovation and commercial viability.  Past RESI events have seen as many as 50% of innovation challenge contestants go on to receive funding or significant partnerships within a year from the competition.

From companies helping to detect oncoming seizures to those developing cost effective ways of growing blood stem cells, this diverse class of competitors is sure to impress. Come check them our yourself in the Exhibition Hall at RESI on MaRs on April 4th!

Therapeutic
 
Diagnostic
Medical Device
 
Healthcare IT
 

RESI on MaRS – Spotlight Your Technology in the RESI Innovation Challenge

2 Feb

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

LSN is gearing up for the upcoming Redefining Early Stage Investments (RESI) Conference in Toronto’s MaRS Discovery District, and we’re seeking fundraising CEOs with the most promising early stage healthcare technologies to showcase in the RESI Innovation Challenge on April 4, 2017.

LSN’s scientific team is preparing to review the RESI Innovation Challenge applications from therapeutics, medtech, diagnostics and healthcare IT companies around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On April 4, 2017, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.

apply-button

APPLICATION DEADLINE: FEB. 15, 2017

Here is what our previous winners are saying about the RESI Innovation Challenge:

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
 
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016

“I love the RESI Innovation Challenge because it is a great way to give our pitch to practice it and try to obtain a scarce resource from these investors. Practicing with these investors is a great way to build relationships and continue that on to the real investment conversations.”

– Niko Skievaski, Co-Founder, Redox

1st Place, RESI@TMCx, June 8, 2015

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

01

“RESI offers small companies like GeneSegues a direct line to potential partners and potential investors in a small setting conducive to relationship building and conversation. The Innovation Challenge was a particularly great way to introduce our company to a broader audience than I could meet with personally which allowed us to leverage the showcasing of our technology more efficiently.”

-Laura M. Brod,Chief Executive Officer,GeneSegues Therapeutics

-1st Place, RESI @TMCx, April 11, 2016

Compelling New Technology Startups Selected RESI@JPM Innovation Challenge

29 Dec

By Dennis Ford, Founder & CEO, LSN

The 11th Redefining Early Stage Investments (RESI) Conference will be joining the JPM fray for our largest event yet on January 10th in San Francisco. We’re excited to announce the early stage life science companies that will be participating in the RESI Innovation Challenge.

The 30 participating companies have been hand-selected by LSN’s scientific review committee based on the innovative nature of their core technology and how well-positioned each is to capitalize on their respective market opportunities.

Therapeutics
 
Digital Health
 

Diagnostics
 

Medtech Devices
 

Tips on How to Improve Your RESI Innovation Challenge Application – And Your Investor Pitch

3 Nov

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

The LSN Innovation Challenge is a competition held at every RESI Conference that provides early-stage companies with a unique opportunity to showcase their technologies at a meeting typically attended by 400 – 500 investors. LSN invites thirty top-tier early-stage fundraising companies to pitch their technologies in a poster format at a venue that provides ready access to a range of investors. The RESI Innovation Challenge has become an exciting event at each RESI meeting that attracts a lot of attention from entrepreneurs and investors alike.

The LSN scientific review team spends a lot of time reviewing applications, that now number in the hundreds, prior to selecting the top thirty. As the Innovation Challenge application deadline draws near (November 18th, folks!), we thought we would share with you how we select the winners. LSN’s scientific review team has compiled some tips on how to submit a compelling Innovation Challenge application.

Keep in mind that, while the following is focused on the Innovation Challenge application itself, the criteria and the tips we provide are also relevant for the fundraising process. Many of the questions we ask are similar to what investors will ask when you are out fundraising.

How do you achieve a high score on your application?

The LSN scientific review team uses a detailed rubric with a 200-point scoring system. Companies are stack-ranked on their scores and we invite the top 30 to present at RESI. Our evaluation process is based not only on scientific merit, but also on how ready the company is to present to an investor (“investor-readiness”). A high scoring company might have a transformational technology that can address a high unmet need using a novel approach or target. In addition to innovation, differentiation, unmet need, and market fit, investors are keenly interested in a broad IP position, an experienced management team and CEO with top-tier advisors, and strategic alliances with manufacturing and clinical partners (if the company is at that stage). LSN also looks at whether the company has “investor-ready” marketing material (executive summary, pitch deck, website).

Application Tips

Clearly describe your technology.

Like any marketing material, you need to be clear. Be sure to understand and answer the questions fully. Instead of saying “my company has a proprietary treatment for many critical illnesses”, it would be much clearer to say, “we are developing an IND-ready small molecule asset for breast cancer by activating natural killer cells.”

Lack of clarity will diminish your chances to participate in the Innovation Challenge.

Be realistic with your answers.

The team frequently reviews applications that don’t adequately highlight the competition. Novel products typically do have competitor’s products that precede them. The key point is to highlight how your technology differentiates itself from competitors.

For example, competitors for your disease-modifying therapeutic may only treat disease symptoms. You should identify existing therapeutics and highlight how your technology may offer a disease-modifying alternative.

Explain your current company status in detail.

Outline your current status, as well as provide your view of the strategic direction of your company. When describing your management team, avoid ambiguous statements such as, “CEO is an experienced entrepreneur”. Instead, provide details that highlight the CEO’s experience – years as an entrepreneur, number and names of companies exited, background expertise, etc.

Summarize near-term and long-term strategy.

If you do not have certain criteria, such as a strategic alliance or IP, it’s OK. State your current standing and provide what steps you are currently taking to reach that milestone.

For Alliances and Collaborations, summarize key relationships – focus on KOLs, medical centers, big pharma, and clinical and manufacturing partners. If there is no signed agreement, stating any verbal relationships would be helpful. If you don’t have issued patents yet, state how many patent applications you have filed or are planning to file. Providing us your strategy is better than a simple yes or no.

Provide enough information but don’t go over-board.

Spend more than 5 minutes on this application, but don’t spend 5 hours. Your answers should be brief, but reasonably detailed. We have received hastily done applications that lacked key information—which quickly received a low score and didn’t make the cut. The questions are all straight-forward that you should be comfortable in answering and have down pat. Remember, your executive summary should include answers to many of these questions already.

Send us your marketing material.

If you have marketing material, send it. We do read it and it can help your score. This includes your pitch deck, executive summary, website, videos – any supplemental material that can boost our understanding of your technology and whether your company is investor-ready. The application provides limited space. While this forces you to get straight to the point, supplemental material explains what an application sometimes doesn’t allow (i.e. figures, graphs, pipeline, non-confidential data, etc.)

Overall, applying for the Innovation Challenge is great practice for fundraising companies. For those who have yet to apply, be sure to take note of these suggestions and apply here before November 18th!

237521341025992000

resi-san-francisco-2017